Tenaya Therapeutics is trading 5.02% down at $0.54 on October 13, 2026, with no verified company-specific announcement or event explaining the decline.

  • Recent TN-401 RMAT designation and trial updates are earlier news, not a newly reported catalyst for this session.
  • Biotech shares are also under pressure: XBI is down about 2% in the provided sector context, while the broader market is nearly flat.
  • Current-session trading volume and activity details were not available in the provided price context.